Observational Study Evaluating Cardiac Amyloidosis in Adults with Severe Aortic Valve Stenosis Using Echocardiography, CT, Tc99-SPECTCT, and Cardiac MRI

What this Trial Is About

Researchers are investigating the presence and characteristics of cardiac amyloidosis in adults with severe degenerative aortic valve stenosis AS undergoing evaluation for transcatheter aortic valve implantation TAVI. This observational study focuses on detecting amyloidosis, a condition that overlaps with features seen in AS and may affect patient outcomes after TAVI. The study uses advanced imaging techniques to identify amyloid deposits and assess their impact on heart function and prognosis. Participants will undergo clinically indicated imaging tests such as technetium-99m phosphonate SPECTCT and computed tomography CT to detect and quantify cardiac amyloidosis. For patients with abnormal imaging results, cardiac magnetic resonance imaging CMR will be performed to further characterize heart tissue changes. These imaging methods provide non-invasive assessments combining anatomical and functional information to improve diagnosis and understanding of cardiac amyloidosis in this population. During the study, participants will have standardized clinical follow-ups at 6, 12, and 24 months to monitor cardiac health and any undesirable cardiac events. Researchers will analyze imaging biomarkers alongside clinical outcomes to determine the prevalence and prognostic value of cardiac amyloidosis. The study does not interfere with routine clinical care and aims to gather important observational data over a total period of up to two years.

Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR)